Synergy between oxacillin and manuka honey sensitizes methicillin-resistant Staphylococcus aureus to oxacillin

Rowena E. Jenkins* and Rose Cooper

Centre for Biomedical Sciences, Cardiff School of Health Sciences, Cardiff Metropolitan University, Western Avenue, Cardiff CF5 2YB, Wales, UK

*Corresponding author. Tel: +44-(0)-2920-416452; Fax: +44-(0)-2920-416982; E-mail: rojenkins@cardiffmet.ac.uk

Received 13 December 2011; returned 1 February 2012; revised 7 February 2012; accepted 9 February 2012

Objectives: Honey is an ancient wound remedy that has recently been introduced into modern clinical practice in developed countries. Manuka honey inhibits growth of methicillin-resistant Staphylococcus aureus (MRSA) by preventing cell division. In Gram-negative bacteria a synergistic interaction between honey and antibiotics has been suggested. We aimed to determine the effect of manuka honey on oxacillin resistance in MRSA.

Methods: Inhibition of MRSA by manuka honey and oxacillin separately and in combination was tested by disc diffusion, Etest strips, serial broth dilution, chequerboards and growth curves.

Results: Manuka honey and oxacillin interacted synergistically to inhibit MRSA. Manuka honey reversed oxacillin resistance in MRSA, and down-regulation of mecR1 was found in cells treated with manuka honey.

Conclusions: Microarray analysis showed that exposure of MRSA to inhibitory concentrations of manuka honey resulted in down-regulation of mecR1. Here we demonstrated that subinhibitory concentrations of honey in combination with oxacillin restored oxacillin susceptibility to MRSA. Other honey and antibiotic combinations must now be evaluated.

Keywords: MRSA, MecR1, honey

Introduction

Since its emergence in 1961, methicillin-resistant Staphylococcus aureus (MRSA) has become a significant burden on public health globally. Epidemic strains EMRSA-15 and EMRSA-16 (NCTC 13142 and NCTC 13143, respectively) have been most commonly associated with bacteraemia in the UK.1 With the low number of antimicrobial agents under development, innovative alternatives must be found.

Re-examination of ancient remedies such as garlic, green tea and honey has generated optimism about finding inhibitors for antibiotic-resistant pathogens. Honey has been used for millenia as a topical treatment for wounds and modern wound dressings containing honey are now available on formularies in many developed countries. Registered products include medical grade honey in tubes, ointments, gels, impregnated onto non-adherent dressings or alginate, and non-sticky flexible honey sheets. All are sterilized by gamma irradiation. Many products contain manuka honey produced by bees foraging on manuka bushes in New Zealand. Manuka honey has been shown to eradicate MRSA from colonized wounds and to inhibit MRSA in vitro by interrupting cell division.2 Although β-lactams are not effective against MRSA, combinations of tea extracts and β-lactams have been demonstrated to restore methicillin susceptibility.1 Methicillin resistance in MRSA is conferred by the mec gene complex, where mecA is regulated by MecR1 and MecI; blocking the mecR1/blaR1 pathway restored antibiotic susceptibility in MRSA.4 The aim of this study was to investigate whether combinations of manuka honey and oxacillin acted synergistically to increase susceptibility of MRSA to oxacillin.

Materials and methods

EMRSA-15 NCTC 13142 was used throughout this study. Oxacillin susceptibility was determined by antibiotic susceptibility testing (AST) according to the BSAC guidelines, except that Mueller–Hinton agar (MHA) (Oxoid, Cambridge, UK) was used with 5 μg oxacillin discs (Oxoid, Cambridge, UK).3 The MIC of oxacillin (Sigma, Dorset, UK) was determined by serial doubling dilution in Mueller–Hinton broth (MHB) (Oxoid, Cambridge, UK) in microtitre plates and with oxacillin Etest strips (bioMérieux) on MHA.

The MIC of sterile manuka honey, which was free from antibiotics, was determined in microtitre plates by dilution in MHB as above, except that dilutions varying by 1% (w/v) intervals were used instead of a doubling dilution series.

To identify interaction between oxacillin and manuka honey, oxacillin susceptibility of MRSA was determined by AST and by Etest strips as...
described above with MHA containing either 2.5% or 5% (w/v) manuka honey (subinhibitory concentrations). Similarly, the effect of including 5% (w/v) manuka honey in MHB on the MIC of oxacillin against MRSA was determined in microtitre plates. To investigate synergistic interaction between oxacillin and manuka honey against MRSA, a chequerboard was set up in microtitre plates as previously described; doubling dilutions of oxacillin (256–0.125 mg/L) were dispensed into successive rows and stepwise dilutions of manuka honey varying by 1% (w/v) intervals in successive columns.6 The fractional inhibition concentration index (FICI) was calculated for each combination using the following formula:

\[
FICI = \frac{\text{MIC of oxacillin}}{\text{MIC of oxacillin alone}} + \frac{\text{MIC of manuka honey}}{\text{MIC of manuka honey alone}}
\]

where FIC of oxacillin is the MIC of oxacillin in combination/MIC of oxacillin alone, and FIC of manuka honey is the MIC of manuka honey in combination/MIC of manuka honey alone. The results were interpreted as follows: \( \geq 0.5 \), synergy; \( >0.5 \) to \( \geq 4 \), additivity; and \( >4 \), antagonism.7

Time–kill curves for EMRSA-15 were performed using MHB with varying concentrations of oxacillin and manuka honey in microtitre plates incubated at 37°C in a Tecan Infinite plate reader. Optical density was monitored at 550 nm at hourly intervals for 24 h. Growth of MRSA was also monitored with subinhibitory combinations of oxacillin and manuka honey in MHB.

Microarray analysis was performed on RNA extracted from cultures of EMRSA-15 grown in MHB with and without 10% (w/v) honey for four hours. RNA was isolated using an SV Total RNA isolation kit (Promega) and cDNA prepared using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturers’ instructions. RNA was then processed, hybridized, stained and scanned on Affymetrix arrays according to the manufacturers’ instructions for prokaryotic target preparation.

All experiments were done with three biological replicates and mean values are presented here. The fold changes are corrected and normalized to account for background noise.


### Results

Resistance of MRSA to oxacillin was confirmed by AST (where zones of inhibition were not seen) and by Etest strips and broth dilution, where the MIC of oxacillin was found to be 64 mg/L (Table 1). The MIC of manuka honey against MRSA determined by broth dilution was 6% (w/v) or 60000 mg/L. When subinhibitory concentrations of manuka honey were incorporated into MHA to investigate effects on oxacillin susceptibility of MRSA by AST, inhibition zones of 32 mm diameter around 5 μg oxacillin discs were observed with 5% (w/v) manuka honey. This reversal of oxacillin resistance in MRSA by manuka honey was also observed by testing combinations of oxacillin and manuka honey using Etest strips (Table 1), broth dilutions and chequerboards (Table 1).

![Figure 1](http://jac.oxfordjournals.org/)

**Figure 1.** Growth curves of MRSA in MHB. MRSA grown in MHB alone (line with no symbols), MRSA in MHB containing 0.5 mg/L oxacillin (asterisks), MRSA in MHB containing 5% (w/v) manuka honey (filled squares) and MRSA in MHB containing 5% (w/v) manuka honey and 0.25 mg/L oxacillin (filled circles). Vertical bars indicate standard deviation.

<table>
<thead>
<tr>
<th>Assays</th>
<th>MIC oxacillin with no addition (mg/L)</th>
<th>MIC containing 5% (w/v) manuka honey (mg/L)</th>
<th>MIC manuka honey (mg/L)</th>
<th>FIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etest strip</td>
<td>64</td>
<td>0.075</td>
<td>60000</td>
<td>0.001 + 0.000000125 = 0.001</td>
</tr>
<tr>
<td>Broth dilution</td>
<td>64</td>
<td>0.06</td>
<td>60000</td>
<td>0.001 + 0.0000001 = 0.001</td>
</tr>
<tr>
<td>Chequerboards</td>
<td>64</td>
<td>0.25</td>
<td>60000</td>
<td>0.001 + 0.000004 = 0.001</td>
</tr>
<tr>
<td>Time–kill curves</td>
<td>64</td>
<td>0.25</td>
<td>60000</td>
<td>0.001 + 0.000004 = 0.001</td>
</tr>
</tbody>
</table>

Assays were performed on at least three occasions and no variation in endpoints was found.

### Table 1. Susceptibility of MRSA to oxacillin and manuka honey

<table>
<thead>
<tr>
<th>Assays</th>
<th>MIC oxacillin with no addition (mg/L)</th>
<th>MIC containing 5% (w/v) manuka honey (mg/L)</th>
<th>MIC manuka honey (mg/L)</th>
<th>FIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etest strip</td>
<td>64</td>
<td>0.075</td>
<td>60000</td>
<td>0.001 + 0.000000125 = 0.001</td>
</tr>
<tr>
<td>Broth dilution</td>
<td>64</td>
<td>0.06</td>
<td>60000</td>
<td>0.001 + 0.0000001 = 0.001</td>
</tr>
<tr>
<td>Chequerboards</td>
<td>64</td>
<td>0.25</td>
<td>60000</td>
<td>0.001 + 0.000004 = 0.001</td>
</tr>
<tr>
<td>Time–kill curves</td>
<td>64</td>
<td>0.25</td>
<td>60000</td>
<td>0.001 + 0.000004 = 0.001</td>
</tr>
</tbody>
</table>

manuka honey in combination was used (Figure 1). FICI values were <0.5 and indicated that oxacillin and manuka honey in combination act synergistically to inhibit MRSA at concentrations below the individual MIC values (Table 1).

Microarray analysis showed that the mecR1 gene product was down-regulated by a factor of 3 in MRSA treated with 10% (w/v) manuka honey for 4 h.

Discussion

Synergy between honey and antibiotics has been investigated previously, but unconvincing data were collected, FICI values were not calculated and mechanisms were not suggested.8 Our findings indicate that sub-lethal concentrations of manuka honey have a marked effect in enhancing the susceptibility of MRSA to oxacillin. As honey can be used undiluted in dressing wounds, 6% is an easily achievable concentration. The down-regulation of mecR1 might explain our observations. Methicillin resistance in MRSA is conferred by the mec gene complex; mecA encodes a penicillin-binding protein (penicillin-binding protein 2a (PBP 2a)) with low binding affinity for β-lactam antibiotics. This allows peptidoglycan biosynthesis to continue in the presence of β-lactams. Regulation of mecA is via mecR1, which codes for a two-component sensor/signal transducer protein, and mecI, which codes for a repressor protein.9 Oxacillin is a β-lactam that has long been used in characterizing antibiotic susceptibility in MRSA and finding synergy between it and honey gives a rationale for testing further combinations. Manuka honey has already been demonstrated not to select for honey-resistant strains, and using antibiotics in combination with honey ought to reduce risks of further antibiotic resistance emerging.10

Reversal of oxacillin resistance in MRSA has been reported for extracts of Camellia sinensis (green tea), Salvia miltiorrhiza (red sage) and Glycyrrhiza uralensis (Chinese liquorice), and the prospect of using combinations of phytochemicals and antibiotics or anticancer drugs in conventional medicine has been raised. Another approach to the restoration of susceptibility of MRSA to methicillin has been to use an antisense oligonucleotide to block the mecR1-mediated signalling pathway, but this is currently not available commercially.9

Manuka honey was re-introduced into modern medicine in 1999. It has been shown to inhibit MRSA effectively in vitro and in vivo. The findings reported here suggest that in vitro this combination could be beneficial. However, in vivo work would need to be conducted to determine whether sufficient penetration of honey and antibiotic is likely to occur in clinical conditions such as wound infections or chronic leg ulcers; if so, patients could potentially benefit from these findings. The presence of manuka honey was shown in this study to restore susceptibility of MRSA to oxacillin; molecular analysis indicated that honey also affected the regulation of the mecR1 gene, possibly accounting for the restored susceptibility seen here.

Acknowledgements

We thank Megan Musson and Peter Giles at Cardiff University CBS Facility (http://medicine.cf.ac.uk/en/translation-innovation-engagement/support_... services/central-biotechnology-services/cbs-facilities/) for performing the microarray analysis.

Funding

This work was supported by The Waterloo Foundation and Sir Halley Stewart Trust.

Transparency declarations

R. C. has received grants from the BSAC, the Society for General Microbiology, the European Wound Management Association, the University of Waikato (in collaboration with the National Honey Board), the Waterloo Foundation, the UWIC Foundation and the Sir Halley Stewart Trust. Sponsorship to attend scientific meetings has been received from Capilano, Derma Sciences Inc. and Mainlyce; consultancy has been undertaken for Aspen Medical, Brightwake Ltd, Comvita UK, Derma Sciences Inc., Medlock Medical, Medihoney and North American Center for Continuing Medical Education. Remuneration for presentations has been received from the Tissue Viability Society, American Professional Wound Care Association, Derma Sciences Inc., Comvita UK, World Union of Wound Healing Societies and numerous beekeeping organizations. R. E. J.: none to declare.

References